- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01767324
Site Selection for Intracutaneous Saline Delivery
July 31, 2017 updated by: FluGen Inc
Exploratory Evaluation of Injection Sites in Healthy Subjects Receiving Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array
The goal of this exploratory study is to select the optimal body site for intracutaneous delivery of 0.5 milliliters of saline from the FLUGEN 101.2 microneedle-based device.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Test ability to inject saline into various sites on body.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Melbourne, Florida, United States, 32935
- Accelovance Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to read and/or understand and sign the Informed Consent Form
Exclusion Criteria:
- Medical history of acute or chronic skin disease
- Active skin allergy or acute skin infection, tattoo(s), scars, sunburn or skin abnormalities at any prospective injection site
- Hirsute at any prospective injection site
- Diabetes
- High levels of anxiety or depression or history of psychosis
- Abuse of alcohol or use of other drugs of abuse including tobacco
- Pregnant or breastfeeding women
- Any medical condition that may interfere with study protocol adherence including completion of study activities
- Foreseeable inability to complete the study as scheduled.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Injection to deltoid
Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
|
Deliver 0.5 milliliters of saline intradermally
|
Experimental: Injection to forearm
Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
|
Deliver 0.5 milliliters of saline intradermally
|
Experimental: Injection to thigh
Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
|
Deliver 0.5 milliliters of saline intradermally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective is to evaluate the safety and tolerability/reactogenicity of saline delivery from the FLUGEN 101.2 microneedle-based device as evidenced by change of dose site appearance over time.
Time Frame: 30 minutes, 24 hours, 1 week
|
Observe injection sites for change of appearance post-dose including wheal formation or resolution.
|
30 minutes, 24 hours, 1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A secondary objective of this study is to evaluate the mechanical elimination of fluid from the device.
Time Frame: 3 minutes
|
Evaluate ability of device to dispense targeted dose volume.
|
3 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Renee Herber, FluGen Inc
- Principal Investigator: Murray A Kimmel, DO, Accelovance
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
January 9, 2013
First Submitted That Met QC Criteria
January 10, 2013
First Posted (Estimate)
January 14, 2013
Study Record Updates
Last Update Posted (Actual)
August 2, 2017
Last Update Submitted That Met QC Criteria
July 31, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- FGN-NSR-2012-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracutaneous Drug Delivery
-
Shiraz University of Medical SciencesCompletedInterferential Current Drug DeliveryIran, Islamic Republic of
-
Moens MaartenCompletedTelemedicine | Intrathecal Drug Delivery | Implantable PumpBelgium
-
Postgraduate Institute of Medical Education and...CompletedPediatric Cardiac Surgery | Intraoperative Awareness | Automated Drug DeliveryIndia
-
Chelsea and Westminster NHS Foundation TrustRoyal College of Surgeons of EnglandUnknownThermography | Laser Doppler Blood Flow | Spectrophotometric Intracutaneous AnalysisUnited Kingdom
-
Erasme University HospitalHopital FochCompletedHemodynamic Instability | Complication of Anesthesia | General Anesthetic Drug Overdose | Adverse Effect of Intravenous Anesthetics, Sequela | Drug Delivery System Malfunction | Underdosing of Other General AnestheticsBelgium
-
University of TorontoO-Two Medical TechnologiesUnknownFeasibility | Comfort | Nitrous Oxide | Dentistry | Drug Delivery System | Drug Administration, InhalationCanada
-
Ethem Unal, M.D., PhD, Associate Prof of Surgery...UnknownPreterm Birth | Preterm Labor | Preterm Labor Without Delivery | Side Effect of Drug | Preterm Labor With Preterm Delivery in Third Trimester | Calcium-Channel Blockers Toxicity
-
Rambam Health Care CampusRecruitingCesarean Delivery Affecting Fetus | Delivery ComplicationIsrael
-
Alzahraa Ismail Ragheb GodaUnknownDelivery ,Complications,Maternal | Delivery,Complication,FetalEgypt
-
The Reading Hospital and Medical CenterRecruitingPregnancy Related | Cesarean Delivery Affecting Fetus | Delivery ComplicationUnited States
Clinical Trials on Injection to deltoid
-
Mayo ClinicWithdrawn
-
Ministry of Health, KuwaitNot yet recruiting
-
Federal University of São PauloCompletedAnkle Injuries | Ankle Fractures | Ligament Rupture | Deltoid Ligament; Sprain (Strain) (Ankle)Brazil
-
Liming ChengUnknown
-
Goztepe Training and Research HospitalRecruitingAnkle Fractures | Ligament Rupture | Ligament InjuryTurkey
-
Centre Francois BaclesseNot yet recruitingRecurrent Cancer | Previous Radiation
-
Oznur UzunRecruitingLow Back Pain, Mechanical | Facet Syndrome of Lumbar SpineTurkey
-
University of AberdeenNHS GrampianCompletedAbdominal Pain | Abdominal Cutaneous Nerve Entrapment SyndromeUnited Kingdom
-
Hadassah Medical OrganizationUnknownInterventional Study | Biological Therapy for Chronic Anal Fissure | Treatment by Biological Factors - Activated MacrophagesIsrael
-
Hadassah Medical OrganizationWithdrawnLow Ovarian Reserve | Poor Quality OocytesIsrael